



Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children

 Jorge A. Soto,^{a,b,c}  Felipe Melo-González,^{a,b,c}  Cristián Gutierrez-Vera,^{a,d}  Bárbara M. Schultz,^{a,b}  Roslye V. Berríos-Rojas,^{a,b}  Daniela Rivera-Pérez,^{a,b}  Alejandro Piña-Iturbe,^{a,b} Guillermo Hoppe-Elsholz,^{a,b} Luisa F. Duarte,^{a,b} Yaneisi Vázquez,^{a,b} Daniela Moreno-Tapia,^{a,b} Mariana Ríos,^{a,b} Pablo A. Palacios,^{a,d} Richard Garcia-Betancourt,^{a,d} Álvaro Santibañez,^{a,d} Gaspar A. Pacheco,^{a,b} Constanza Mendez,^{a,b} Catalina A. Andrade,^{a,b} Pedro H. Silva,^{a,b} Benjamín Diethelm-Varela,^{a,b} Patricio Astudillo,^e Mario Calvo,^f Antonio Cárdenas,^g Marcela González,^{h,i} Macarena Goldsack,^e Valentina Gutiérrez,^{e,j} Marcela Potin,^{e,k} Andrea Schilling,^{l,dd} Lorena I. Tapia,^{m,n} Loreto Twele,^{o,ee} Rodolfo Villena,^{p,q} Alba Grifoni,^r Alessandro Sette,^{r,s} Daniela Weiskopf,^r Rodrigo A. Fasce,^t Jorge Fernández,^t Judith Mora,^t Eugenio Ramírez,^t Aracelly Gaete-Argel,^{a,u} Mónica L. Acevedo,^{a,u} Fernando Valiente-Echeverría,^{a,u} Ricardo Soto-Rifo,^{a,u} Angello Retamal-Díaz,^{a,v} Nathalia Muñoz-Jofré,^w PedCoronaVac03CL Study Group, Xing Meng,^x Qianqian Xin,^x Eduardo Alarcón-Bustamante,^{y,zaa} José V. González-Aramundiz,^{bb} Nicole Le Corre,^e María Javiera Álvarez-Figueroa,^{bb} Pablo A. González,^{a,b} Katia Abarca,^{a,e} Cecilia Perret,^e Leandro J. Carreño,^{a,d} Susan M. Bueno,^{a,b} Alexis M. Kalergis^{a,b,cc}

^aMillennium Institute on Immunology and Immunotherapy, Santiago, Chile

^bDepartamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile

^cDepartamento de Ciencias Biológicas, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile

^dPrograma de Inmunología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile

^eDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

^fInstituto de Pediatría, Facultad de Medicina, Universidad Austral de Chile, Valdivia, Chile

^gDepartamento de Ciencias Médicas, Facultad de Medicina y Odontología, Universidad de Antofagasta, Antofagasta, Chile

^hHospital Dr. Gustavo Fricke, Valparaíso, Chile

ⁱDepartamento de Pediatría, Universidad de Valparaíso, Valparaíso, Chile

^jUnidad de Infectología Pediátrica, Servicio de Pediatría, Hospital Dr. Sotero del Río, Santiago, Chile

^kClínica San Carlos de Apoquindo, Red de Salud UC Christus, Santiago, Chile

^lFacultad de Medicina, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile

^mDepartamento de Pediatría y Cirugía Infantil Norte, Hospital Roberto del Río, Santiago, Chile

ⁿPrograma de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile

^oHospital Puerto Montt, Puerto Montt, Chile

^pHospital Exequiel González Cortés, Santiago, Chile

^qFacultad de Medicina, Departamento de Pediatría y Cirugía Infantil Campus Sur, Universidad de Chile, Santiago, Chile

^rCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA

^sDepartment of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, California, USA

^tDepartamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile

^uLaboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile

^vDepartamento de Biotecnología, Facultad de Ciencias del Mar y de Recursos Biológicos, Universidad de Antofagasta, Antofagasta, Chile

^wDepartamento de Tecnología Médica, Facultad de Ciencias de la Salud, Universidad de Antofagasta, Antofagasta, Chile

^xSinovac Biotech, Beijing, China

^yFaculty of Mathematics, Pontificia Universidad Católica de Chile, Santiago, Chile

^zMillennium Nucleus on Intergenerational Mobility: From Modelling to Policy (MOVI), Santiago, Chile

^{aa}Interdisciplinary Laboratory of Social Statistics, Faculty of Mathematics, Pontificia Universidad Católica de Chile, Santiago, Chile

^{bb}Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago, Chile

^{cc}Departamento de Endocrinología, Facultad de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

Editor Kanta Subbarao, NIAID, NIH

Copyright © 2022 Soto et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Susan M. Bueno, sbueno@bio.puc.cl, or Alexis M. Kalergis, akalergis@bio.puc.cl.

The authors declare a conflict of interest. XM and QX are SINOVA Biotech employees and contributed to the conceptualization of the study and did not participate in the analysis or interpretation of the data presented in the manuscript. A.S. is a consultant for Gritstone, Flow Pharma, Arccturus, Immunoscape, CellCarta, OxfordImmunotech and Avalia. La Jolla Institute for Immunology (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no conflict of interest.

Received 6 May 2022

Accepted 21 September 2022

Published 16 November 2022

^{dd}Departamento de Pediatría, Clínica Alemana de Santiago, Santiago, Chile

^{ee}Facultad de Medicina y Ciencia, Universidad San Sebastián, Puerto Montt, Chile

Jorge A. Soto, Felipe Melo-González, Cristián Gutierrez-Vera, and Bárbara M. Schultz contributed equally to this article. The author's order of names was agreed with authors and the corresponding authors.

ABSTRACT Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. The inactivated vaccine CoronaVac has been shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China. Here, we report interim safety and immunogenicity results of a phase 3 clinical trial for CoronaVac in healthy children and adolescents in Chile. Participants 3 to 17 years old received two doses of CoronaVac in a 4-week interval until 31 December 2021. Local and systemic adverse reactions were registered for volunteers who received one or two doses of CoronaVac. Whole-blood samples were collected from a subgroup of 148 participants for humoral and cellular immunity analyses. The main adverse reaction reported after the first and second doses was pain at the injection site. Four weeks after the second dose, an increase in neutralizing antibody titer was observed in subjects relative to their baseline visit. Similar results were found for activation of specific CD4⁺ T cells. Neutralizing antibodies were identified against the Delta and Omicron variants. However, these titers were lower than those for the D614G strain. Importantly, comparable CD4⁺ T cell responses were detected against these variants of concern. Therefore, CoronaVac is safe and immunogenic in subjects 3 to 17 years old, inducing neutralizing antibody secretion and activating CD4⁺ T cells against SARS-CoV-2 and its variants. (This study has been registered at [ClinicalTrials.gov](https://clinicaltrials.gov) under no. NCT04992260.)

IMPORTANCE This work evaluated the immune response induced by two doses of CoronaVac separated by 4 weeks in healthy children and adolescents in Chile. To date, few studies have described the effects of CoronaVac in the pediatric population. Therefore, it is essential to generate knowledge regarding the protection of vaccines in this population. Along these lines, we reported the anti-S humoral response and cellular immune response to several SARS-CoV-2 proteins that have been published and recently studied. Here, we show that a vaccination schedule consisting of two doses separated by 4 weeks induces the secretion of neutralizing antibodies against SARS-CoV-2. Furthermore, CoronaVac induces the activation of CD4⁺ T cells upon stimulation with peptides from the proteome of SARS-CoV-2. These results indicate that, even though the neutralizing antibody response induced by vaccination decreases against the Delta and Omicron variants, the cellular response against these variants is comparable to the response against the ancestral strain D614G, even being significantly higher against Omicron.

KEYWORDS CoronaVac, phase 3 clinical trial, pediatric, SARS-CoV-2, COVID-19, vaccines, variants of concern, immunogenicity, safety

The inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine CoronaVac, developed by Sinovac Life Sciences Co., Ltd. (Beijing, China), has shown favorable safety and immunogenicity results in adults (1–5). In children and adolescents between 3 and 17 years old, this vaccine induces neutralizing antibodies against SARS-CoV-2 after immunization with two doses (6). Similar results have been shown with Pfizer BNT162b2 and Moderna mRNA-1273 in children between 6 and 11 years old and adolescents (7, 8). However, these reports lack a characterization of the cellular immune responses elicited in children and adolescents after immunization and the neutralizing capacity of antibodies against SARS-CoV-2 variants of concern (VOC). Here, we further characterize the immune responses elicited in participants between 3 and 17 years old 4 weeks after the second dose of CoronaVac applied in a 4-week interval (or 0- to 28-day vaccination schedule) in a phase 3 trial in Chile. The present study was generated during an epidemiological period with a high presence of SARS-CoV-2 Delta variant and a low number of cases caused by the Omicron variant.




FIG 1 Study profile, enrolled participants, and cohort included in this study from September 10th to December 31st 2021. (A) Timeline of the vaccination schedule and sample collection. Text in red denotes time points at which blood draws occurred. (B) Study profile of subjects that received 1 dose (orange boxes) and 2 doses (light blue boxes) until December 31st 2021 by age and safety group.

The administration of this vaccine in the participants between 3 and 17 years old is safe and elicits significant levels of both humoral and cellular immunity in adolescents and children against the original strain of SARS-CoV-2 and VOC.

RESULTS

Population included in the study. Nine hundred sixty-three participants were recruited between September 10th and December 31st; 482 of them were male (51.1%), with an average age of 6.35 years (standard deviation [SD], 3.12 years). The study included children and adolescents 3 to 17 years old who were inoculated with two doses of 3 μg (600 Standard Unit) of CoronaVac in a 4-week interval (0- to 28-day schedule) (Fig. 1A). Figure 1B shows the enrolled population and distribution by age, dose, and safety group.

Adverse events identified in children and adolescents vaccinated with CoronaVac.

(i) Immediate adverse events. In the 30 min postvaccination, local pain was reported by 3.8% and 1.7% of subjects in the 3- to 11-year age group after the first and second doses, respectively, and 2.2% and 8.2% in the 12- to 17-year age group. Pain adverse event (AE) was statistically significantly higher in adolescents than children after the second dose ($P = 0.003$). The rest of the local AEs were reported in 2% or fewer participants, without age or dose differences, such as pruritus localized in the site of injection of two children of 3 to 11 years old after the first dose (see Table S1 in the supplemental material).

Systemic immediate AEs were reported in less than 1% of the 3- to 11-year age group. Meanwhile, the 12- to 17-year age group reported mainly headache after the first and second doses at 2.2% and 1.2%, respectively. They reported no other systemic AEs after the first dose, and one adolescent reported self-limited pruritus after the second dose (Table S1).

(ii) Nonimmediate adverse events. Only the safety group reported nonimmediate AEs. However, immediate AEs, postvaccination AEs of grade 3 or more, any medical consult due to an EA, and serious AEs/AEs of special interest (SAEs/AESI) were recorded for all participants. The rationale for this measure is that, as this is a multicenter study performed in several countries, the safety data measured in the subgroups of each center are representative of the entire population studied. The most frequent local nonimmediate AE was pain, observed in around 15% of subjects in the 3- to 11-year age




FIG 2 Frequency and duration of nonimmediate local and systemic adverse events by dose and age group. Shown are the total number of nonimmediate local AEs presented by 653 participants in the 3- to 11-year age group and 46 participants in the 12- to 17-year age group after their first dose of CoronaVac (A) or 336 participants in the 3- to 11-year age group and 45 participants in the 12- to 17-year age group after their second dose of CoronaVac (B). (C and D) Total number of systemic AEs presented by 653 participants in the 3- to 11-year age group and 46 participants in the 12- to 17-year age group after the first (C) or the second (D) dose of CoronaVac. Black bars correspond to the 3- to 11-year age group, and white bars correspond to the 12- to 17-year age group. The values on the bars represented as percentages correspond to the number of the AEs evaluated over the total number of participants of that age range.

group after the first dose and 8% after the second dose ($P = 0.003$). In the 12- to 17-year age group, pain was reported in around 25% of subjects after each dose, which was significantly higher than the frequency reported in the 3- to 11-year age group after the second dose ($P = 0.006$). The remaining local AEs were reported in less than 5% of subjects in the 3- to 11-year age group and less than 10% in the 12- to 17-year age group. The nonimmediate AEs lasted between 0 and 2 days. For systemic AEs, the overall duration was 0 to 2 days. However, some AEs, such as “skin or mucosa abnormality,” maintained durations of 4.3 days (dose 1) and 5 days (dose 2) for the 3- to 11-year-old group. The duration of “nausea” in subjects 12 to 17 years old after dose 1 was 10.7 days. Finally, in the “other” category, the duration of AEs was 2.3 to 4.3 days for both groups evaluated after vaccination (Fig. 2). These percentages represent solicited AEs within the first week. Nonsolicited AEs are reported up to 28 days after each dose and SAE/AESI throughout the study.

Systemic AEs were reported at a frequency of less than 10% each (Fig. 2). The most frequent systemic AEs were fever for children 3 to 11 years old and headache and fatigue for adolescents. Comparison by age and dose showed a significantly higher frequency of headache in adolescents than in children after both doses ($P = 0.002$ and 0.003) and a higher frequency of fatigue in the 3- to 11-year age group after the first dose than after the second dose ($P = 0.012$). There were 8 allergic reactions only in the 3- to 11-year-old group, and only 2 of them were considered probably related to vaccination. However, none of the volunteers suffered anaphylaxis (Table S2). The severities of systemic AEs were grade 1 in 62 to 79% of participants and grade 3 in only 1.7 to 2.7%. There was no grade 4 AE. All previous medical histories were recorded, but specific symptoms such as headaches were not. Symptoms of myocarditis, such as fatigue, are specifically asked about on the reactogenic daily card, but any other symptoms

and hospitalizations should also be reported. In this way, we would be able to detect any picture suggestive of myocarditis.

There was just one nonrelated SAE reported in the period (a 3-year-old participant hospitalized for 24 h due to influenza A infection).

Two doses of CoronaVac increase antibody titers with neutralizing capacity in children and adolescents. Ninety-two participants from the immunogenicity branch, who received two doses of CoronaVac, were included in this study (Fig. S1). Clinical data from these patients are described in Table S3. Samples from the placebo group were not analyzed as they did not receive two doses prior to starting the data blind. The samples analyzed were obtained before vaccination (baseline) and 4 weeks after the second dose. IgG against the S1 receptor-binding domain (RBD) of SARS-CoV-2 was significantly increased in plasma samples obtained 4 weeks after the second dose of CoronaVac compared to the baseline sample in both age groups (Fig. 3A). Accordingly, we detected significant neutralizing capacity by a surrogate virus neutralization test (sVNT) in plasma in both age groups 4 weeks after the second dose (Fig. 3B), which is in line with previous reports in adult cohorts (2). Similarly, when analyzing neutralization with a conventional VNT (cVNT), we observed a significant increase in both age groups (Fig. 3C and Table S4A). In addition, the seropositivity reached 96% for the 3- to 11-year age group and 94.5% for the 12- to 17-year age group. However, 100% of seropositivity was found for the samples analyzed by sVNTs 4 weeks after the second dose in both groups, while it reached 100% for the 3- to 11-year age group and 88.2% for the 12- to 17-year age group for cVNT (Table S4A). When comparing the humoral immune responses of both age groups 4 weeks after the second dose, significant differences were found only for cVNT assays (Fig. 3D to F). These results were corroborated with the seroresponse (geometric mean 2nd dose plus 4 weeks versus the baseline) found, which was higher for the 3- to 11-year age group than the 12- to 17-year age group (Fig. 3G).

Of note, volunteers enrolled in the study were considered seronegative subjects determined by a rapid IgG/IgM antibody test, excluding those seropositive for further immunogenicity assays. The results show that some volunteers presented total and neutralizing anti-SARS-CoV-2 antibodies before vaccination (Fig. 3A and C). These results could be explained by volunteers undergoing asymptomatic infections, whose titers were not detected by the rapid diagnostic tests carried out during the enrollment. These differences in the inclusion criteria could be associated with the increased sensitivity of the techniques used in these trials compared to the rapid test used at enrollment.

To rule out any possible infection that occurred during the evaluation period, volunteers who had any type of symptoms related to a SARS-CoV-2 infection underwent a diagnostic test using reverse transcription-quantitative PCR (RT-qPCR).

CoronaVac induces a robust activation and memory population of CD4⁺ T cells in children and adolescents. We also analyzed the cellular immune responses following two doses of CoronaVac in children and adolescents, which, to our knowledge, has not been reported in other studies with CoronaVac or mRNA vaccines against SARS-CoV-2. Compared to the baseline samples, we observed a significant increase in CD4⁺ T cell activation 4 weeks after the second dose of CoronaVac upon stimulation with four megapools (MPs) comprising peptides from the S, R (all but S), M, and N viral proteins (Fig. S2A and B). A significant increase in the activation of CD4⁺ T cells was found in the 12- to 17-year age group for all the MPs evaluated. In contrast, the increase in the activation of CD4⁺ T cells for the 3- to 11-year age group was statistically significant for the S and N stimuli only (Fig. 4A). Additionally, the induction of memory markers in activated CD4⁺ T cells induced 4 weeks after the second dose was compared to the baseline samples (Fig. S2C and D). An increase in the ratio of memory cells with respect to the baseline samples was observed in the 12- to 17-year age group in the presence of all stimuli (Fig. 4B). For the 3- to 11-year age group, an increase in the ratio of memory cells with respect to the baseline samples was observed only in the presence of the S and N stimuli (Fig. 4B).




FIG 3 CoronaVac immunization induces anti-S1 RBD antibodies with neutralizing capacities in children and adolescents after two vaccine doses. (A) Total IgG anti-S1 RBD antibodies were detected by chemiluminescence in the plasma of participants immunized with CoronaVac. Results were obtained from 25 participants in the 3- to 11-year age group and 36 participants in the 12- to 17-year age group. (B) Neutralizing antibodies were detected in plasma using a surrogate viral neutralization test (svNT), which quantifies the interaction between S1 RBD and hACE2 on ELISA plates. Results were obtained from 55 participants in the 3- to 11-year age group and 36 participants in the 12- to 17-year age group. Data are represented as WHO international units per milliliter. (C) Neutralizing antibody titers in plasma were evaluated using a conventional virus neutralizing test (cvNT) in 27 children in the 3- to 11-year age group and 34 participants in the 12- to 17-year age group. A comparison between the 3- to 11-year age group and the 12- to 17-year age group was performed for total IgG anti-S1 RBD antibodies (D), svNT (E), and cvNT (F). Seroresponse was calculated as the ratio of the geometric means of the 2nd dose plus 4 weeks to baseline (G). The numbers above each set of individual data points show the geometric mean, and the error bars indicate the 95% confidence interval (CI). A two-way ANOVA was followed by Šídák's multiple-comparison test (A to C) and unpaired t test (D to F) on the log₁₀-transformed data to evaluate differences. ***, *P* < 0.001; ns, nonsignificant.

Moreover, secretion of the cytokines interleukin-2 (IL-2) and gamma interferon (IFN-γ) by peripheral blood mononuclear cells (PBMCs) stimulated with MPs of peptides was evaluated using Luminex. We observed a significant increase in IL-2 secretion in response to the S and R MPs and M and N MPs in the 12- to 17-year age group (Fig. S3A to D). In the case of the 3- to 11-year age group, we observed a significant increase in response to the S, M, and N MPs. In contrast, we did not observe a significant increase in IFN-γ release after the MP stimulation for participants of ages 12 to 17 years (Fig. S3E to H). However, the production of IFN-γ in response to the S, M, and N MPs showed a significant increase in the 3- to 11-year age group (Fig. S3E to H). No differences were found in IL-4 levels after vaccination, measured by Luminex technology (data not shown). Levels of IFN-γ and IL-4 were also evaluated by enzyme-linked immunosorbent spot (ELISPOT), but we did not observe significant differences in any of these cytokines upon stimulation with SARS-CoV-2 MPs (Fig. S4A to H). We were not able to evaluate IL-2 by ELISPOT due to the limited number of cells obtained from each volunteer.

We did not observe an increase in CD8⁺ activation-induced marker-positive (AIM⁺) T cells with MP CD8A and CD8B in any age group following the second dose of CoronaVac compared to the baseline sample (data not shown). However, we found




FIG 4 Changes in activation-induced marker (AIM) expression in CD4⁺ T cells and memory AIM⁺ CD4⁺ T cells specific for SARS-CoV-2 after two doses of CoronaVac in children and adolescents. AIM⁺ CD4⁺ T cells were quantified in peripheral blood mononuclear cells (PBMCs) from participants that received two doses of CoronaVac by flow cytometry upon stimulation with megapools (MPs) of peptides derived from SARS-CoV-2 proteins. The percentages of activated AIM⁺ CD4⁺ T cells (OX40⁺, CD137⁺) were determined upon stimulation for 24 h with MPs S, R, M, and N in baseline samples and with samples obtained 4 weeks after the second dose. Data from flow cytometry were normalized against dimethyl sulfoxide (DMSO). Percentages of AIM⁺ CD4⁺ T cells against MPs S, R, M, and N were obtained from a total of 51 participants in the 3- to 11-year age group and 38 participants in the 12- to 17-year age group (A). Memory AIM⁺ CD4⁺ T cells were quantified in PBMCs from participants that received two doses of CoronaVac upon stimulation with MPs of peptides derived from SARS-CoV-2 proteins. The percentages of memory-activated AIM⁺ CD4⁺ T cells (OX40⁺, CD137⁺, CD45RA⁻, CCR7^{+/-}) were determined upon stimulation for 24 h with MPs S, R, M, and N in samples obtained at baseline and 4 weeks after the second dose. Data from flow cytometry were normalized against DMSO. Memory AIM⁺ CD4⁺ T cells against the MPs S, R, M, and N were obtained from a total of 51 participants in the 3- to 11-year age group and 38 participants in the 12- to 17-year age group (B). The numbers above each individual point data set represent the mean, and the error bars are the 95% CI. A two-way ANOVA followed by Šidák's multiple-comparison test was used to assess differences in panels A and B. *, *P* < 0.05; **, *P* < 0.01; ***, *P* < 0.001; n.s., nonsignificant.

significant differences for memory CD8⁺ AIM⁺ T cell analyses (Fig. S5). Representative flow cytometry plots of memory CD8⁺ AIM⁺ T cells for participants in the 3- to 11-year age group (Fig. S5A) and 12- to 17-year age group (Fig. S5B) are shown. A significant increase in memory CD8⁺ AIM⁺ T cells after vaccination with CoronaVac was observed only upon stimulation with MP CD8A in the 3- to 11-year age group (Fig. S5C). Both groups found no differences upon stimulation with MP CD8B (Fig. S5D).

Neutralizing antibodies and specific T cells induced by two doses of CoronaVac in children and adolescents recognize Delta and Omicron variants of SARS-CoV-2.

To assess whether CoronaVac induces immune responses against SARS-CoV-2 VOC, we evaluated by a pseudotyped virus neutralization assay (pVNT) the neutralizing antibody levels against VOC Delta and Omicron comparing them to the D614G strain (which was used as a control as it has a Spike RBD identical to the ancestral strain but contains a mutation outside the RBD, which is also contained in most of the VOC) (Fig. 5). A 1.9-fold reduction relative to strain D614G was found in neutralization against Delta, while a 15.8-fold reduction was observed against Omicron (Fig. 5A). The percentages of seropositivity showed an important reduction for the Omicron variant (Table S4B). When we compared the responses between both age groups, we did not find significant differences for the D614G and Delta variants. However, a significantly higher level of neutralizing antibodies against Omicron was observed in the 3- to 11-year age group (Fig. 5B). A mild but insignificant reduction of AIM⁺ T cells against MP-S of the Delta variant (1.4-fold reduction) and a significant increase against MP S of the Omicron variant (3.5-fold increase) were observed, compared to the response obtained for MP S of the wild-type (WT) strain (Fig. 5C). This T cell response was




FIG 5 Quantification of circulating neutralizing antibodies and AIM⁺ CD4⁺ T cells against SARS-CoV-2 variants Delta and Omicron in participants that received two doses of CoronaVac. (A) Neutralizing antibodies were detected in the plasma of 88 participants 4 weeks after the second dose of CoronaVac, using a pseudotyped virus neutralization test (pVNT). Data are expressed as the reciprocal of the highest dilution preventing 80% of the infection (ID₈₀). Numbers above the bars show the GMT, and the error bars indicate the 95% CI. (B) Neutralizing antibody levels between 52 participants in the 3- to 11-year age group and 36 participants in the 12- to 17-year age group against D614G, Delta, and Omicron variants are shown. (C and D) AIM⁺ CD4⁺ T cells against the variants Delta and Omicron were measured by flow cytometry. (C) Results were obtained from a total of 59 participants. (D) Results shown by age group (29 participants from the 3- to 11-year age group and 30 participants from the 12- to 17-year age group). The numbers in red (decrease) or blue (increase) next to the statistics show the fold change of the response against the variant relative to the WT or D614G strain. (E) The correlations between neutralizing antibody titers and AIM⁺ percentages against the Omicron variant were evaluated. The Pearson correlation coefficient (*r*) and the *P* value are indicated in each scatterplot. A one-way ANOVA followed by Dunnett's multiple-comparison test (A and C) and two-way ANOVA followed by Šidák's multiple-comparison test (B and D) were performed to assess differences. *, *P* < 0.05; ***, *P* < 0.001; n.s., nonsignificant.

equivalent in both age groups (Fig. 5D). While Fig. 5B and D suggest a possible correlation between the humoral and cellular responses against Omicron in the 3- to 11-year age group, it was not possible to find a positive correlation between antibody titers against Omicron and CD4⁺ T cell response (Fig. 5E).

DISCUSSION

Multiple vaccines against SARS-CoV-2 have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. Here, we report that CoronaVac has a good safety profile in children and adolescents

in Chile, comparable to what was reported by Han et al. (6), with pain as the main AE in both age groups but statistically more frequently reported in adolescents than in children. Most AEs were mild or moderate, and no SAEs related to the vaccine were reported. This is in line with previous reports in adults vaccinated with CoronaVac in Chile and other countries, which have mainly reported mild or moderate AEs in participants 18 to 59 years old and older than 60 years (2, 4, 5). Of note, we acknowledge that the safety follow-up reported here is relatively short term. Indeed, for rare SAEs such as myocarditis, the sample size may be small and the observation time too short to detect any cases.

We also show that two doses of CoronaVac, administered in a 4-week interval, stimulate the induction of both total and neutralizing antibodies in participants 3 to 17 years old 4 weeks after the second dose. This is the first report of total IgG antibodies anti-S1 RBD expressed as WHO international units in children and adolescents vaccinated with CoronaVac, allowing their comparison to other vaccine platforms. However, clinical trials in children and adolescents have only reported neutralizing antibodies against SARS-CoV-2 (7, 8).

Our results suggest that CoronaVac promotes CD4⁺ T cell responses against SARS-CoV-2, which can be protective against infection and/or severe disease. Here, we report a significant increase in CD4⁺ AIM⁺ T cells in response to MPs but no differences in CD8⁺ AIM⁺ T cells, in line with the results previously observed in vaccinated adults, which indicate that CoronaVac is better at inducing CD4⁺ T cell responses. We did not observe significant differences between age groups in CD4⁺ AIM⁺ T cells, suggesting that children and adolescents can activate CD4⁺ T cell responses against SARS-CoV-2 following vaccination. The 12- to 17-year age group exhibit increased CD4⁺ T cell activation against all the SARS-CoV-2 MP evaluated, which indicate that the vaccine stimulates cellular immunity not only against the Spike protein but also against the M and N proteins, consistent with the fact that this is an inactivated virus vaccine containing the major structural proteins. However, the 3- to 11-year age group did not exhibit increased CD4⁺ T cell activation against the M protein. Consistent with this, we show a significant increase in IL-2 secretion in response to S and N MPs in both age groups, whereas we detected a significant increase in response to the M MPs only in subjects 12 to 17 years old. As previously reported in adults vaccinated with CoronaVac (2), we did not observe an increase in IL-4 production in stimulated cells, indicating that CoronaVac stimulates a Th1 profile in vaccinated children and adolescents. Similarly, we observed a significant increase in IFN- γ production using Luminex technology in the 3- to 11-year age group upon stimulation with the MP-S but not in the other age group and in the presence of other MPs. However, this significant difference may be attributed to the high levels of IFN- γ in some subjects but is not necessarily representative of the whole group. In line with this, we did not observe significant differences in this cytokine using ELISPOT. Furthermore, we observed an increase in the frequency of memory CD4⁺ AIM⁺ T cells in response to SARS-CoV-2 MP-S and slightly higher induction of memory T cells in subjects 12 to 17 years old than in subjects 3 to 11 years old. This increased ratio of memory CD4⁺ T cells suggests that the vaccine may induce durable CD4⁺ T cell responses. However, evaluation of these responses at later time points following the second dose are required to confirm this idea. These results agree with reports showing that memory T cell responses against SARS-CoV-2 structural proteins increase with age (9).

Moreover, we evaluated the neutralization using a pseudotyped virus against variants Delta and Omicron compared to the ancestral strain D614G and found decreased antibody neutralization capacity against these variants. While we observed high seropositivity against D614G (100%), lower seropositivity against the variant Omicron was found (45.5%) (Table S4B) in line with previous reports indicating lower protection against VOC in adult cohorts after two doses of CoronaVac (10–12). However, a booster dose of CoronaVac has been shown to increase virus neutralization of the VOC Gamma and Delta (13). Thus, a booster dose of CoronaVac may be required to increase virus

neutralization of circulating SARS-CoV-2 variants in children and adolescents. This is consistent with our studies and another trial conducted in Israel (14).

On the other hand, we observed that both age groups elicited CD4⁺ AIM⁺ T cells in response to MPs from the variants Delta and Omicron. We did not observe significant differences in CD4⁺ AIM⁺ T cells against the Delta variant compared to the ancestral strain, but surprisingly, an increase against the Omicron variant was observed. Several studies in vaccinated adults have shown that CD4⁺ T cell responses against VOC are conserved, and cross-reactive T cells against the Omicron variant have been reported (15, 16). However, it is unclear why this pediatric population exhibits increased CD4⁺ AIM⁺ T cells against the Omicron variant, and further research is required to understand these results. In this sense, a study in volunteers 12 to 16 years old vaccinated with two doses of ChAdOx1 nCoV-19 or mRNA vaccines showed an effect on the cellular response against the Omicron variant similar to that reported by us, suggesting that the cellular response is more stable against other SARS-CoV-2 variants than the humoral response.

One of the main limitations of this study is the impossibility of repeating a large part of the assays, given that the volumes of blood extracted from the volunteers were very small, especially for the younger subjects. Since, in this study, the monitoring of possible SARS-CoV-2 infections by RT-qPCR was performed for symptomatic cases only, we cannot rule out the presence of asymptomatic cases during the study. Despite this, a study evaluating long-lived immunity observed that seronegative participants who received two doses of BNT162b2 presented a response similar to the reported in this investigation against variants such as Omicron (17), suggesting a low, if any, the contribution of asymptomatic cases to our results. These results indicate that CoronaVac is safe in children and adolescents and induces both humoral and cellular responses able to recognize the VOC Delta and Omicron.

Finally, CoronaVac shows promising results in the induction of the immune response against SARS-CoV-2 and the variants of interest. However, to date, there is limited information regarding the long-term immune response in the pediatric population, whose information is essential for the implementation of vaccination schedules. In this sense, a study comparing adult volunteers vaccinated with two doses of CoronaVac and receiving a booster with CoronaVac, BNT162b2, and ChAdOx1 after 6 to 8 months showed that the best immune response is induced when the booster is a vaccine different than CoronaVac. However, no differences were found in the three groups evaluated when the humoral response was compared 30 or 100 days after the booster (18), suggesting that a booster dose with either CoronaVac or other vaccine platforms may be beneficial in pediatric individuals. Further studies are required to assess the immune responses using a heterologous or homologous vaccination schedule.

MATERIALS AND METHODS

Study design. This study is a global multicenter, randomized, double-blind, and placebo-controlled phase 3 clinical trial that aims to assess the safety, efficacy, and immunogenicity of CoronaVac among children aged 6 months to 17 years. The administration of placebo and vaccine was in a ratio of 1:1. Four countries participated in this study, including South Africa, Malaysia, Philippines, and Chile (ClinicalTrials registration no. NCT04992260). This report will focus only on the study performed in Chile for participants that received CoronaVac. In Chile, this trial has been conducted at 11 different sites, eight in the center of the country (seven in Santiago and one in Valparaíso), two in the South (Puerto Montt and Valdivia), and one in the North (Antofagasta) of Chile. The study protocol was conducted according to the current *Tripartite Guidelines for Good Clinical Practices*, the Declaration of Helsinki (19), and local regulations. This trial was approved by each Institutional Ethical Committee (ID 210616012) and the Chilean Public Health Institute (ISP Chile, no. 20674/21). Written informed consent was obtained from the parent(s) or legal representative(s) of the child before enrollment. Assent was obtained from individuals from 7 years old. Participants did not receive any payment for their participation. The study included children and adolescents 3 to 17 years old who were inoculated with two doses of 3 μ g (600 SU) of CoronaVac in a 4-week interval (0- to 28-day schedule) (Fig. 1A). Before the volunteers were vaccinated, a negative rapid antigen test result was required. Exclusion criteria included, among others, a history of confirmed symptomatic SARS-CoV-2 infection, pregnancy, allergy to vaccine components, and

immunocompromised condition. Well-controlled medical conditions were allowed. A complete list of inclusion/exclusion criteria is provided in the supplemental material.

Study population and outcomes. Participants were assigned to the age groups 3 to 5 (children), 6 to 11 (children), and 12 to 17 (adolescents) years and immunogenicity subgroup, safety subgroup, or nonsubgroup. The nonsubgroup, which included only children 3 to 5 years old with vaccine and placebo, did not have a daily follow-up after the vaccination and only had a follow-up if the members of the group reported serious adverse events (SAEs) and adverse events of special interest (AESI). The initial protocol had a placebo for the 3- to 5-year-old arm and was a double-blind study, but this was modified to an open-label study due to the approval of the emergency vaccination to the general population in Chile. Therefore, the nonsubgroup (3 to 5 years old) was redistributed to the immunogenicity and safety arms. After the unblinding, 158 children who received a placebo were reenrolled to be immunized with CoronaVac. For the present study, we combined the children in the 3- to 11-year age group (Fig. 1B). Besides, only volunteers with two doses of CoronaVac until 31st December 2021 were included in these analyses. Participants not considered in this article received their second dose after 31st December 2021. The safety group includes registration of every local and systemic nonimmediate adverse events (AEs) 7 days after vaccination and any other AE until 28 days after each dose. For all participants, immediate AEs (30 min postvaccination) and SAEs as well as AESI were recorded. The safety studies considered the subjects enrolled until 31st December 2021, enrolled from the 11 centers in Chile. The safety data on the other countries participating in the study were not included since the global safety data set of the entire study is only managed by the sponsoring company, Sinovac, and until the closing date of this article, there was no information on all of the countries.

The study aims were to evaluate the immunogenicity of CoronaVac in a subgroup of participants 4 weeks after 2 doses and the frequency of solicited immediate (first 30 min postdose) and nonimmediate adverse events (AEs) that occur during 7 days after each dose, stratified by age group (3 to 11 and 12 to 17 years old). The frequency of SAEs/AESI and any other AEs represents events that occur 28 days after each dose, and the frequency of any SAE/AESI represents events that occur 12 months after the second dose.

Sample collection. Subjects enrolled in one specific clinical center (CL01, Marcoleta) were assigned to the immunogenicity branch, which considered 148 volunteers. Blood samples were obtained in heparinized tubes before administration of the first dose (baseline) and 4 weeks after the second dose as described in Fig. S1 in the supplemental material. Samples were used to obtain plasma and peripheral blood mononuclear cells (PBMCs) and stored at -80°C (plasma) and -170°C (PBMCs) until humoral and cellular immunity analyses were performed. The sample size included in each experimental analysis is described in Fig. S1.

Procedures. IgG anti-S1 RBDs of SARS-CoV-2 were tested using ADVIA Centaur XP SARS-CoV-2 IgG (sCOVG) (Siemens) (20, 21), an automated two-step sandwich antibody-binding immunoassay using indirect chemiluminescence. sCOVG was used for quantitative detection expressed in binding antibody units (BAU) per milliliter after interpolating the WHO standard NIBSC code 20/136 calibration (21). The cutoff considered for this methodology was 1.18 U/mL. The presence of circulating antibodies able to block the interaction of the RBD of the S1 subunit of the SARS-CoV-2 Spike protein with the recombinant human angiotensin 2 receptor (hACE2) was evaluated using a surrogate virus neutralization test (sVNT) (Genscript catalog no. L00847-A). A cutoff of $>30\%$ was used to define if samples were positive or not for the presence of anti-SARS-CoV2 neutralizing antibodies. Seropositivity designation and transformation to WHO arbitrary units were described previously (13). As previously reported, conventional virus neutralization tests (cVNTs) to detect neutralization against the ancestral SARS-CoV-2 virus were performed. The neutralization titer was calculated considering 100% inhibition of the virus, which was related to an absence of cytopathic effect on Vero E6 cells (2). A pseudotyped virus neutralization test (pVNT) assay was performed to assess neutralization against SARS-CoV-2 VOC, as previously reported (12, 22) (Text S1). To evaluate the cellular immune response, PBMCs of 60 participants were stimulated with six megapools (MPs) derived from the SARS-CoV-2 proteome (23) (Text S1). MPs of peptides from the S protein of SARS-CoV-2 VOC Delta and Omicron were provided by La Jolla Institute for Immunology (16). Positive and negative controls were included in each assay. The numbers of spot-forming cells (SFCs) for IFN- γ and IL-4 were determined by ELISPOT, and the expression of activation-induced marker (AIM $^{+}$) and memory markers by T cells was evaluated by flow cytometry using a LSR Fortessa X-20 flow cytometer (BD Biosciences). Assays were performed according to the manufacturer's instructions as reported previously (2). Supernatants from PBMCs stimulated for 20 h with SARS-CoV-2 MPs were evaluated using the Luminex technology (R&D Systems, USA) to assess IL-2 and IFN- γ production (Text S1).

The selection of participants for immunogenicity analysis was based on the availability of samples collected from the baseline and 4 weeks post-second dose. In addition, only those subjects who were seronegative at study entry were included.

Statistical analyses. Statistical differences in the immunogenicity results were assessed using a two-way ANOVA followed by Šidák's multiple-comparison test to compare the levels of antibodies 4 weeks after the second dose against the baseline levels in the different age groups (total IgG, sVNT, pVNT, and cVNT). Two-way ANOVA followed by Šidák's multiple-comparison tests was also used for cellular immune response to compare the percentages of AIM $^{+}$, memory AIM $^{+}$ CD4 $^{+}$ T cells, and cytokine secretion 4 weeks after the second dose against the baseline levels in both age groups. A one-way ANOVA followed by Dunnett's multiple-comparison test was used to evaluate total antibodies or cells from variants of SARS-CoV-2. When indicated, the analyses were performed on the \log_{10} -transformed data. Regarding clinical data, adverse events among groups were compared with the chi-square test or Fisher

exact test. The significance level was set at 0.05 for all the analyses. All data were analyzed with GraphPad Prism 9.4.0 or R version 3.6.1.

Data availability. All analyzed and raw data (masked to protect the information of volunteers) are available upon reasonable request to the corresponding authors through email after the publication of this article. A signed data access agreement will be requested to share the data. The study protocol is also available online.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

TEXT S1, DOCX file, 0.1 MB.

FIG S1, TIF file, 0.4 MB.

FIG S2, TIF file, 1.3 MB.

FIG S3, TIF file, 0.4 MB.

FIG S4, TIF file, 0.4 MB.

FIG S5, TIF file, 0.8 MB.

TABLE S1, PDF file, 0.03 MB.

TABLE S2, PDF file, 0.02 MB.

TABLE S3, PDF file, 0.01 MB.

TABLE S4, PDF file, 0.02 MB.

ACKNOWLEDGMENTS

We thank Rami Scharf, Jessica White, and Miren Iturriza-Gomara from PATH for their support with experimental design and discussion. We also thank the Vice Presidency of Research (VRI), the Direction of Technology Transfer and Development (DTD), and the Legal Affairs Department (DAJ) of the Pontificia Universidad Católica de Chile. We are also grateful to the Administrative Directions of the School of Biological Sciences and the School of Medicine of the Pontificia Universidad Católica de Chile for administrative support. We thank Marcela Ferrés (Laboratory of Infectology and Molecular Virology, Pontificia Universidad Católica de Chile) for laboratory support. We are grateful to the members of the independent data safety monitoring committee for oversight and the subjects enrolled in the study for participation and commitment to this trial. Members of the independent data safety monitoring committee are as follows: Xuanyi Wang, Institutes of Biomedical Sciences, Fudan University, Shanghai, China; Lorenz von Seidlein, Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand; Xia Jielai, Military Preventive Medicine School, Air Force Medical University, Xian City, Shanxi Province, China; Dongliang Yang, International Joint Laboratory of Viral Infection and Immunity, Wuhan City, Hubei Province, China; Zhaolong Cao, Pulmonary and Critical Medicine, University of Wuhan, Medical College, Wuhan.

The PedCoronaVac03CL Study was funded by Sinovac Biotech. The National Agency for Research and Development (ANID) through Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) grants 1190156, 1211547, and 1190830 supports R.S.-R., F.V.-E., and A.M.K., respectively. The Millennium Institute on Immunology and Immunotherapy, ANID-Millennium Science Initiative Program ICN09_016 (formerly P09/016-F), supports A.M.K., F.V.-E., K.A., L.J.C., R.S.-R., P.A.G., and S.M.B. The Innovation Fund for Competitiveness FIC-R 2017 (BIP code 30488811-0) supports A.R.-D., S.M.B., P.A.G., and A.M.K. This study was also funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract no. 75N93021C00016 to A.S. and contract no. 75N93019C00065 to A.S. and D.W.

X.M. and Q.X. are SINOVAC Biotech employees, contributed to the conceptualization of the study, and did not participate in the analysis or interpretation of the data presented in the manuscript. A.S. is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Moderna, AstraZeneca, Avalia, Fortress, Repertoire, Gilead, Gerson Lehrman Group, RiverVest, MedaCorp, and Guggenheim. LJ has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no conflict of interest.

Members of the PedCoronaVac03CL Study Group are as follows: at Center CL01 (Marcoleta, Pontificia Universidad Católica de Chile), Patricio Astudillo Paredes, Epifanía Hernández Jara, Héctor Morán Fernández, Javiera Arenas Urra, Stephani Ascui Baeza,

María Olivia Cabrera, José Romero Muñoz, Gonzalo Alarcón Andrade, Rocío Rodríguez Espósito, Anwar Gutiérrez Silva, Fernanda Pérez Gutiérrez, and Alma Muñoz Muñoz; at Center CL02 (Clínica San Carlos de Apoquindo, Pontificia Universidad Católica de Chile), Marcela Potin Santander, Sofia López, and Tania Weil; at Center CL03 (Centro Médico San Joaquín, Pontificia Universidad Católica de Chile), Macarena Goldsack, Deidyland Arenas, Andrea Araya, Javiera Moore, Lorena Pilicita, Vania Valenzuela, Catalina Campos, and Mauricio Soto; at Center CL05 (Clínica Alemana, Universidad del Desarrollo), Andrea Schilling, Alberto Trautmann, Ana Fritis, Daniela Pavez, Javiera Arancibia, Lilian Rubio, Paula Viviani, Vinka Basic, and Cassandra Cárcamo; at Center CL06 (Clínica Valdivia, Universidad Austral), Mario Calvo Gil, Marisol Wenzel, Nicole Carey, and Roberto Burgos; at Center CL07 (Hospital de Puerto Montt), Loreto Twele, Daniel Beltrán, Silvana Grandón, and Carlos Tovar; at Center CL08 (Hospital Gustavo Fricke, Universidad de Valparaíso), Marcela González, Daniela Fuentes, Teresa Ramírez, Mariela Cepeda Corrales, and Nataly Martínez López; at Center CL09 (Complejo Asistencial Sotero del Río), Valentina Gutiérrez, Felipe Reyes, Armando Lavayen, Melissa González, Monserrat Gutiérrez, Noris Rengifo, Carla Ortega, and Florencia Saver; at Center CL10 (Hospital Roberto de Río, Universidad de Chile), Lorena Tapia, Mirta Acuña, Javiera Albornoz, Tania Cariqueo, Alejandro Velásquez, and Yennybeth Leiva Chamorro; at Center CL11 (Hospital de Niños Exequiel González Cortés, U de Chile), Rodolfo Villena, Paola Flores, Francisca Bartsch, Belén Sepúlveda, Daniela Garmendia, and Lorena González; at Center CL12 (Hospital Clínico Universidad de Antofagasta, Universidad de Antofagasta), Antonio Cárdenas, Angello Retamal, Carmen Ludeña, Carolina Hermosilla, Gustavo Keilhold, Francisco Cammarata-Scalisi, Jessica Álvarez, Jessica Romero, Pía Villarroel, Francisca Muñoz, Jorge Maya, Andrés Canales, Margarita K. Lay, Christian Muñoz, and Roylester Araya.

REFERENCES

- Mallapaty S. 2021. WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. *Nature* 594:161–162. <https://doi.org/10.1038/d41586-021-01497-8>.
- Bueno SM, Abarca K, González PA, Gálvez NMS, Soto JA, Duarte LF, Schultz BM, Pacheco GA, González LA, Vázquez Y, Ríos M, Melo-González F, Rivera-Pérez D, Iturriaga C, Urzúa M, Domínguez A, Andrade CA, Berrios-Rojas RV, Canedo-Marroquín G, Covián C, Moreno-Tapia D, Saavedra F, Vallejos OP, Donato P, Espinoza P, Fuentes D, González M, Guzmán P, Muñoz Venturini P, Pérez CM, Potin M, Rojas Á, Fasce RA, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Oyarzún-Arrau A, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Sette A, Zeng G, Meng W, González-Aramundiz JV, Kalergis AM, CoronaVac03CL Study Group. 2022. Safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in a subgroup of healthy adults in Chile. *Clin Infect Dis* 75:e792–e804. <https://doi.org/10.1093/cid/ciab823>.
- Qiang G, Linlin B, Haiyan M, Lin W, Kangwei X, Minnan Y, Yajing L, Ling Z, Nan W, Zhe L, Hong G, Xiaoqin G, Biao K, Yaling H, Jiangning L, Fang C, Deyu J, Yanhui Y, Chengfeng Q, Jing L, Xuejie G, Xiuyu L, Wen S, Dongdong W, Hengming Z, Lang Z, Wei D, Yurong L, Jinxing L, Changgui L, Xiangxi W, Weidong Y, Yanjun Z, Chuan Q. 2020. Development of an inactivated vaccine candidate for SARS-CoV-2. *Science* 369:77–81. <https://doi.org/10.1126/science.abc1932>.
- Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P, Wang L, Zhao G, Ding Y, Zhao Y, Yin W. 2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis* 21:803–812. [https://doi.org/10.1016/S1473-3099\(20\)30987-7](https://doi.org/10.1016/S1473-3099(20)30987-7).
- Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. 2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis* 21: 181–192. [https://doi.org/10.1016/S1473-3099\(20\)30843-4](https://doi.org/10.1016/S1473-3099(20)30843-4).
- Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, Li M, Lian X, Jiao W, Wang L, Shu Q, Wu Z, Zhao Y, Li Q, Gao Q. 2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. *Lancet Infect Dis* 21:1645–1653. [https://doi.org/10.1016/S1473-3099\(21\)00319-4](https://doi.org/10.1016/S1473-3099(21)00319-4).
- Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, Ding B, Dooley J, Girard B, Hillebrand W, Pajon R, Miller JM, Leav B, McPhee R. 2021. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. *N Engl J Med* 385:2241–2251. <https://doi.org/10.1056/NEJMoa2109522>.
- Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, Barnett ED, Muñoz FM, Maldonado Y, Pahud BA, Domachowski JB, Simões EAF, Sarwar UN, Kitchin N, Cunliffe L, Rojo P, Kuchar E, Rämetsä M, Munjal I, Perez JL, Frenck RW, Lagkadinou E, Swanson KA, Ma H, Xu X, Koury K, Mather S, Belanger TJ, Cooper D, Türeci Ö, Dormitzer PR, Şahin U, Jansen KU, Gruber WC. 2022. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. *N Engl J Med* 386:35–46. <https://doi.org/10.1056/NEJMoa2116298>.
- Cohen CA, Li APY, Hachim A, Hui DSC, Kwan MYW, Tsang OTY, Chiu SS, Chan WH, Yau YS, Kaviani N, Ma FNL, Lau EHY, Cheng SMS, Poon LLM, Peiris M, Valkenburg SA. 2021. SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection. *Nat Commun* 12:4678. <https://doi.org/10.1038/s41467-021-24938-4>.
- Fernández J, Bruneau N, Fasce R, Martín HS, Balanda M, Bustos P, Ulloa S, Mora J, Ramírez E. 2022. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies. *J Med Virol* 94:399–403. <https://doi.org/10.1002/jmv.27310>.
- Beltrán-Pavez C, Riquelme-Barrios S, Oyarzún-Arrau A, Gaete-Argel A, González-Stegmaier R, Cereceda-Solis K, Aguirre A, Travisany D, Palma-Vejares R, Barriga GP, Gaggero A, Martínez-Valdebenito C, Le Corre N, Ferrés M, Balcels ME, Fernandez J, Ramírez E, Villarroel F, Valiente-Echeverría F, Soto-Rifo R. 2021. Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile. *Sci Adv* 7: eabe6855. <https://doi.org/10.1126/sciadv.abe6855>.
- Melo-González F, Soto JA, González LA, Fernández J, Duarte LF, Schultz BM, Gálvez NMS, Pacheco GA, Ríos M, Vázquez Y, Rivera-Pérez D, Moreno-Tapia D, Iturriaga C, Vallejos OP, Berrios-Rojas RV, Hoppe-Elsholz G, Urzúa M, Bruneau N, Fasce RA, Mora J, Griffoni A, Sette A, Weiskopf D, Zeng G, Meng W, González-Aramundiz JV, González PA, Abarca K, Ramírez E, Kalergis AM, Bueno SM. 2021. Recognition of variants of concern by antibodies and T cells induced by a SARS-CoV-2 inactivated vaccine. *Front Immunol* 12:747830. <https://doi.org/10.3389/fimmu.2021.747830>.

13. Schultz BM, Melo-González F, Duarte LF, Gálvez NMS, Pacheco GA, Soto JA, Berríos-Rojas RV, González LA, Moreno-Tapia D, Rivera-Pérez D, Ríos M, Vázquez Y, Hoppe-Elsholz G, Andrade-Parra CA, Vallejos OP, Piña-Iturbe A, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W, CoronaVac03CL Study Group, González-Aramundiz JV, González PA, Abarca K, Kalergis AM, Bueno SM. 2022. A booster dose of coronavac increases neutralizing antibodies and t cells that recognize delta and omicron variants of concern. *mBio* 13: e01423-22. <https://doi.org/10.1128/mbio.01423-22>.
14. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, Mizrahi B, Alroy-Preis S, Ash N, Milo R, Huppert A. 2021. BNT162b2 vaccine booster dose protection: a nationwide study from Israel. *medRxiv*. <https://www.medrxiv.org/content/10.1101/2021.08.27.21262679v1>.
15. Gao Y, Cai C, Grifoni A, Müller TR, Niessl J, Olofsson A, Humbert M, Hansson L, Österborg A, Bergman P, Chen P, Olsson A, Sandberg JK, Weiskopf D, Price DA, Ljunggren H-G, Karlsson AC, Sette A, Aleman S, Buggert M. 2022. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. *Nat Med* 28:472–476. <https://doi.org/10.1038/s41591-022-01700-x>.
16. Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, Goodwin B, Rubiro P, Sutherland A, Wang E, Frazier A, Ramirez SI, Rawlings SA, Smith DM, da Silva Antunes R, Peters B, Scheuermann RH, Weiskopf D, Crotty S, Grifoni A, Sette A. 2021. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. *Cell Rep Med* 2:100355. <https://doi.org/10.1016/j.xcrm.2021.100355>.
17. Sieber J, Mayer M, Schmidthaler K, Kopanja S, Camp J v, Popovitsch A, Dwivedi V, Hoz J, Schoof A, Weseslindtner L, Szépfalusi Z, Stiasny K, Aberle JH. 2022. Long-lived immunity in SARS-CoV-2-recovered children and its neutralizing capacity against Omicron. *Front Immunol* 13:882456. <https://doi.org/10.3389/fimmu.2022.882456>.
18. Vargas L, Valdivieso N, Tempio F, Simon V, Sauma D, Valenzuela L, Beltrán C, Castillo-Delgado L, Contreras-Benavides X, Acevedo ML, Acevedo J, Gonzalez RI, Valiente-Echeverría F, Soto-Rifo R, Roseblatt M, Lopez M, Osorio F, Bono MR. 2022. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. *BMC Med* 20:216. <https://doi.org/10.1186/s12916-022-02406-0>.
19. World Medical Association. 2013. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA* 310:2191–2194. <https://doi.org/10.1001/jama.2013.281053>.
20. Irsara C, Egger AE, Prokop W, Nairz M, Loacker L, Sahanic S, Pizzini A, Sonnweber T, Holzer B, Mayer W, Schennach H, Loeffler-Ragg J, Bellmann-Weiler R, Hartmann B, Tancevski I, Weiss G, Binder CJ, Anliker M, Griesmacher A, Hoermann G. 2021. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. *Clin Chem Lab Med* 59:1453–1462. <https://doi.org/10.1515/cclm-2021-0214>.
21. Giavarina D, Carta M. 2022. Improvements and limits of anti SARS-CoV-2 antibodies assays by WHO (NIBSC 20/136) standardization. *Diagnosis* 9: 274–279. <https://doi.org/10.1515/dx-2021-0126>.
22. Acevedo ML, Gaete-Argel A, Alonso-Palomares L, de Oca MM, Bustamante A, Gaggero A, Paredes F, Cortes CP, Pantano S, Martínez-Valdebenito C, Angulo J, le Corre N, Ferrés M, Navarrete MA, Valiente-Echeverría F, Soto-Rifo R. 2022. Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile. *Nat Microbiol* 7: 524–529. <https://doi.org/10.1038/s41564-022-01092-1>.
23. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, Marrama D, de Silva AM, Frazier A, Carlin AF, Greenbaum JA, Peters B, Krammer F, Smith DM, Crotty S, Sette A. 2020. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. *Cell* 181:1489–1501.e15. <https://doi.org/10.1016/j.cell.2020.05.015>.